Information Provided By: 
Fly News Breaks for February 4, 2016
GRFS, HOLX
Feb 4, 2016 | 12:22 EDT
Piper Jaffray analyst William Quirk said he confirmed that Hologic (HOLX) has a developmental assay that could be manufactured and shipped through partner Grifols (GRFS) if organizations like the American Red Cross adopt a blood screening test for Zika virus. Quirk estimates the Zika opportunity could add about $40M-$80M to revenue and 6c-12c to Hologic's annual EPS. He keeps a Neutral rating on the stock, but said he would be "more constructive" if Hologic drops into the low $30 per share area.
News For HOLX;GRFS From the Last 2 Days
There are no results for your query HOLX;GRFS
